Kinetics of 4-fluoroquinolones permeation into saliva

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 4, 1999, Pages 183-191

  Kozjek, F ^a   Suturkova L J ^a   Antolic G ^a   Grabnar, I ^a   Mrhar, A ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

4 Fluoroquinolones; Pharmacokinetics; Saliva concentrations

Indexed keywords

CENIN; CIPROFLOXACIN; NOLICIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VISIREN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SALIVA LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

ADULT; ANTI-INFECTIVE AGENTS; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; DRUG MONITORING; HUMANS; MALE; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; SALIVA;

EID: 0032817107     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199905)20:4<183::AID-BDD178>3.0.CO;2-B     Document Type: Article

References (17)

1. Neuman M. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet 1988; 14: 96-121.
2. Lode H, Höffken G, Prinzing, C, Glatzel P, Wiley R et al. Comparative pharmacokinetics of new quinolones. Drugs 1987; 34 (Suppl 1): 21-25.
3. Sörgel F, Jaehde U, Naber K, Stephan U. Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clin Pharmacokinet 1988; 16 (Suppl 1): 5-24.
4. Zuidema J, Hold KM, de Boer D, Maes RAA. Saliva as a specimen for therapeutic drug monitoring in pharmacies. Pharm Word Sci 1996; 18: 193-194.
5. Takagi K, Hasegawa T, Yamaki K, Suzuki K, Nabeshima T. Secretion of ofloxacin into saliva in patients with respiratory tract infection. Int J Pharmacol Ther Toxicol 1992; 30: 46-50.
6. Wise R. Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues. Am J Medic 1991; 94: 67S-70S.
7. Wise R, Baldwin DR, Andrews JM, Honeybourne D. Comparative pharmacokinetic disposition of fluoroquinolones in the lung. J Antimicrob Chemother 1991; 28: 65-71.
8. Piercy EA, Bawdon RE, Mackowiak PA. Penetration of ciprofloxacin into saliva and nasal secretions and effect of the drug on the aeropharyngeal flora of III Subjects. Antimicrob Agents Chemother 1991; 33: 1645-1646.
9. Schentag JJ, Nix DE. Pharmacokinetics and tissue penetration of quinolones. In: Sipporin C, Meifitz CL, Domagabe JM (eds) The New Generation of Quinolones. New York: Marcel Dekker, 1980; 189-222.
10. Fitton A. The quinolones, an overview of their pharmacology. Clin Pharmacokinet 1992; 22 (Suppl 1): 1-11.
11. Jusko WJ, Milsap RL. Pharmacokinetic principles of drug distribution in saliva. Ann NY Acad Sci 1993; 694: 36-47.
12. El-Yazigi A, Al-Rawithy S. A direct liquid-chromatographic quantitation of ciprofloxacin in microsamples of plasma with fluorimetric detection. Ther Drug Monit 1990; 12: 378-381.
13. Chow SC, Liu JP. Recent statistical developments in bioequivalence trials-a review of the FDA guidance. Drug Inf J 1994; 28: 851-864.
14. Sokal RR, Rolf FJ. Blometry, The Principles and Practice of Statistics in Biological Research. New York: WH Freeman and Company, 1997; 541-546.
15. Posti J. Saliva-plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications. Pharm Acta Helv 1982; 57: 83-92.
16. Posti J. Arzneimittelkonzentrationen im plasma und im speichel-physiologische und pharmakokinetische betrachtungen. Pharma Acta Helv 1979; 54: 191-196.
17. Hansch C, Leo A, Hoeckman D. Exploring QSAR Hydrophobic, Electronic and Stearic Constants. Washington DC: ACS, 1995.